Assignee
OSI PHARMACEUTICALS LLC
US·15 granted patents·7 pending applications·47 citations·filing 2005–2022
Top patents by PatentIndex Score
22 records- 0188US8003806B2Integrin antagonists useful as anticancer agentsOSI PHARMACEUTICALS LLC·Filed 2005·Granted Aug 23, 2011·12 cites·8 claims
- 0287US11253520B2Pulse dosing regimen and methods of treatmentOSI PHARMACEUTICALS LLC·Filed 2020·Granted Feb 22, 2022·2 cites·21 claims
- 0385US10583142B2Pulse dosing regimen and methods of treatmentOSI PHARMACEUTICALS LLC·Filed 2016·Granted Mar 10, 2020·3 cites·21 claims
- 0484US7998688B2Inhibition of EMT induction in tumor cells by anti-cancer agentsOSI PHARMACEUTICALS LLC·Filed 2009·Granted Aug 16, 2011·5 cites·13 claims
- 0583US8377636B2Biological markers predictive of anti-cancer response to kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2008·Granted Feb 19, 2013·7 cites·9 claims
- 0682US9096624B2Amino pyrimidine anticancer compoundsOSI PHARMACEUTICALS LLC·Filed 2013·Granted Aug 4, 2015·6 cites·7 claims
- 0781US7951405B2Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitorOSI PHARMACEUTICALS LLC·Filed 2005·Granted May 31, 2011·2 cites·2 claims
- 0878US8653268B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2013·Granted Feb 18, 2014·2 cites·1 claims
- 0972US11833149B2Pulse dosing regimen and methods of treatmentOSI PHARMACEUTICALS LLC·Filed 2022·Granted Dec 5, 2023·0 cites·29 claims
- 1071US9351974B2Substituted pteridinones for the treatment of cancerOSI PHARMACEUTICALS LLC·Filed 2012·Granted May 31, 2016·2 cites·10 claims
- 1170US8378104B27-aminofuropyridine derivativesOSI PHARMACEUTICALS LLC·Filed 2011·Granted Feb 19, 2013·2 cites·24 claims
- 1267US8383357B2Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2007·Granted Feb 26, 2013·3 cites·2 claims
- 1366US8048621B2Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2008·Granted Nov 1, 2011·1 cites·2 claims
- 1460US8367826B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2011·Granted Feb 5, 2013·0 cites·8 claims
- 1554US2016158235A1Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2015·Application pending·0 cites
- 1650US8022206B2Furo[3,2-C]pyridinesOSI PHARMACEUTICALS LLC·Filed 2009·Granted Sep 20, 2011·0 cites·19 claims
- 1750US2013261306A1Preparation of c-pyrazine-methylaminesOSI PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 1849US2013253197A1Fused bicyclic kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 1949US2013210026A1Biological markers predictive of anti-cancer response to kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 2045US2014057352A1Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formationOSI PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 2144US2014018375A1Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 2242US2013005733A1Combination anti-cancer therapyOSI PHARMACEUTICALS LLC·Filed 2011·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →